Literature DB >> 15605615

Efficacy of latanoprost and timolol maleate in black and white patients.

Naris Kitnarong1, Yuling Zhao, Peter A Netland, Alexander R Kent.   

Abstract

The purpose of this study was to assess the efficacy of latanoprost 0.005% and timolol maleate 0.5% in black and white patients with elevated intraocular pressure (IOP). This double-masked, randomized, 2-period crossover study included 39 eyes in 22 patients with primary open-angle glaucoma or ocular hypertension. After a 2- to 4-week washout period, patients were randomly assigned to receive either vehicle placebo in the morning and latanoprost in the evening or timolol maleate twice daily for 6 weeks. Then, after a 4-week washout period, patients received the opposing treatment for 6 weeks. Both latanoprost and timolol maleate significantly lowered IOP from baseline in both black and white patients. Latanoprost treatment was associated with lower mean IOP compared with timolol treatment in black patients (P = .013 at 8 AM, P = .19 at 10 AM). At 10 AM at the end of the treatment period, the mean +/- SD change from baseline IOP in black patients receiving latanoprost was significantly greater than that of white patients (-10.2 +/- 7.0 and -5.9 +/- 2.5 mm Hg, respectively; P = .042). The mean +/- SD change from baseline IOPs in black patients was not significantly different from that in white patients at 8 AM at the end of the treatment period for the latanoprost group and at 8 AM and 10 AM at the end of the treatment period for the timolol maleate group. In white patients, the change from baseline IOP in light (grade 1) irises was not significantly different from dark (grade 5) irises after treatment with either latanoprost or timolol maleate. In summary, intraocular pressure after treatment with latanoprost was lower than that after timolol treatment in black patients with primary open-angle glaucoma or ocular hypertension, and at 1 of 2 timepoints, latanoprost caused a significantly greater reduction of IOP in black patients than in white patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605615     DOI: 10.1007/bf02850153

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  5 in total

1.  Glaucoma Treatment Outcomes in Open Angle Glaucoma Patients of African Descent.

Authors:  Brent Siesky; Alon Harris; Aditya Belamkar; Ryan Zukerman; Avery Horn; Alice Verticchio Vercellin; Kristen A Mendoza; Paul A Sidoti; Francesco Oddone
Journal:  J Glaucoma       Date:  2022-03-29       Impact factor: 2.290

2.  Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial.

Authors:  Nevin W El-Nimri; Sasan Moghimi; Rafaella C Penteado; Elham Ghahari; Diya Yang; Nicole Brye; James Proudfoot; Jiun L Do; Andrew Camp; Matthew Salcedo; Veronica Rubio; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2022-05-06       Impact factor: 5.488

3.  Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma.

Authors:  Ciro Costagliola; Francesco Parmeggiani; Gianni Virgili; Giuseppe Lamberti; Carlo Incorvaia; Paolo Perri; Claudio Campa; Adolfo Sebastiani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-11-15       Impact factor: 3.117

Review 4.  New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.

Authors:  Nikki A Mehran; Sapna Sinha; Reza Razeghinejad
Journal:  Eye (Lond)       Date:  2019-11-06       Impact factor: 3.775

5.  The management of glaucoma and intraocular hypertension: current approaches and recent advances.

Authors:  Robert J Noecker
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.